# Biomarker Guided Therapies in Stage A/B Heart Failure

> **NCT02230891** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 58 (actual)

## Conditions studied

- Hypertension
- Diabetes
- Cardiovascular Disease

## Interventions

- **DRUG:** Carvedilol
- **DRUG:** Spironolactone
- **OTHER:** Usual care

## Key facts

- **NCT ID:** NCT02230891
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2020-12-15
- **Final completion:** 2020-12-15
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230891, "Biomarker Guided Therapies in Stage A/B Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02230891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*